Comments
Loading...

SAB Biotherapeutics Analyst Ratings

SABSNASDAQ
Logo brought to you by Benzinga Data
Consensus Rating1
Buy
Highest Price Target1
$20.00
Lowest Price Target1
$6.00
Consensus Price Target1
$11.17

SAB Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:SABS | Benzinga

SAB Biotherapeutics Inc has a consensus price target of $11.17 based on the ratings of 7 analysts. The high is $20 issued by Chardan Capital on May 15, 2025. The low is $6 issued by HC Wainwright & Co. on April 1, 2025. The 3 most-recent analyst ratings were released by Chardan Capital, HC Wainwright & Co., and Chardan Capital on May 15, 2025, May 14, 2025, and April 1, 2025, respectively. With an average price target of $16.67 between Chardan Capital, HC Wainwright & Co., and Chardan Capital, there's an implied 810.75% upside for SAB Biotherapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Jan
2
Apr
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.1
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Chardan Capital
HC Wainwright & Co.
HC Wainwright & Co.
Craig-Hallum
Oppenheimer

1calculated from analyst ratings

Analyst Ratings for SAB Biotherapeutics

Buy NowGet Alert
05/15/2025Buy Now992.9%Chardan Capital
Keay Nakae54%
$20 → $20MaintainsBuyGet Alert
05/14/2025Buy Now446.45%HC Wainwright & Co.
Emily Bodnar37%
→ $10Assumes → BuyGet Alert
04/01/2025Buy Now992.9%Chardan Capital
Keay Nakae54%
$25 → $20MaintainsBuyGet Alert
04/01/2025Buy Now227.87%HC Wainwright & Co.
Edward White45%
$6 → $6ReiteratesBuy → BuyGet Alert
01/29/2025Buy Now1266.12%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
01/29/2025Buy Now227.87%HC Wainwright & Co.
Edward White45%
$6 → $6ReiteratesBuy → BuyGet Alert
11/07/2024Buy Now1266.12%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
10/09/2024Buy Now501.09%Craig-Hallum
Albert Lowe26%
→ $11Initiates → BuyGet Alert
09/12/2024Buy Now555.74%Oppenheimer
Leland Gershell66%
$12 → $12ReiteratesOutperform → OutperformGet Alert
09/09/2024Buy Now1266.12%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
08/28/2024Buy Now555.74%Oppenheimer
Leland Gershell66%
→ $12Initiates → OutperformGet Alert
08/12/2024Buy Now1266.12%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
08/12/2024Buy Now227.87%HC Wainwright & Co.
Edward White45%
$6 → $6ReiteratesBuy → BuyGet Alert
06/07/2024Buy Now337.16%Brookline Capital
Kumaraguru Raja19%
→ $8Initiates → BuyGet Alert
05/21/2024Buy Now227.87%HC Wainwright & Co.
Edward White45%
$6 → $6ReiteratesBuy → BuyGet Alert
05/21/2024Buy Now1266.12%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
04/16/2024Buy Now227.87%HC Wainwright & Co.
Edward White45%
$6 → $6ReiteratesBuy → BuyGet Alert
04/16/2024Buy Now1266.12%Chardan Capital
Keay Nakae54%
$25 → $25MaintainsBuyGet Alert
04/02/2024Buy Now1266.12%Chardan Capital
Keay Nakae54%
$3 → $25MaintainsBuyGet Alert
04/02/2024Buy Now227.87%HC Wainwright & Co.
Edward White45%
$10 → $6MaintainsBuyGet Alert
01/08/2024Buy Now446.45%HC Wainwright & Co.
Edward White45%
$1 → $10ReiteratesBuy → BuyGet Alert
11/14/2023Buy Now-45.36%HC Wainwright & Co.
Edward White45%
$2 → $1MaintainsBuyGet Alert
10/05/2023Buy Now—Ladenburg Thalmann
Jeffrey Cohen28%
—DowngradeBuy → NeutralGet Alert
08/21/2023Buy Now9.29%HC Wainwright & Co.
Edward White45%
$4 → $2MaintainsBuyGet Alert
06/21/2023Buy Now118.58%HC Wainwright & Co.
Edward White45%
→ $4ReiteratesBuy → BuyGet Alert
06/16/2023Buy Now118.58%HC Wainwright & Co.
Edward White45%
→ $4ReiteratesBuy → BuyGet Alert
06/15/2023Buy Now63.93%Chardan Capital
Keay Nakae54%
→ $3ReiteratesBuy → BuyGet Alert
05/17/2023Buy Now118.58%HC Wainwright & Co.
Edward White45%
→ $4ReiteratesBuy → BuyGet Alert
04/27/2023Buy Now63.93%Chardan Capital
Keay Nakae54%
→ $3Reiterates → BuyGet Alert
04/13/2023Buy Now118.58%HC Wainwright & Co.
Edward White45%
→ $4Reiterates → BuyGet Alert
04/03/2023Buy Now118.58%HC Wainwright & Co.
Edward White45%
→ $4Reiterates → BuyGet Alert
11/29/2022Buy Now118.58%HC Wainwright & Co.
Edward White45%
→ $4Initiates → BuyGet Alert
08/11/2022Buy Now63.93%Chardan Capital
Keay Nakae54%
$7 → $3MaintainsBuyGet Alert

FAQ

Q

What is the target price for SAB Biotherapeutics (SABS) stock?

A

The latest price target for SAB Biotherapeutics (NASDAQ:SABS) was reported by Chardan Capital on May 15, 2025. The analyst firm set a price target for $20.00 expecting SABS to rise to within 12 months (a possible 992.90% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for SAB Biotherapeutics (SABS)?

A

The latest analyst rating for SAB Biotherapeutics (NASDAQ:SABS) was provided by Chardan Capital, and SAB Biotherapeutics maintained their buy rating.

Q

When was the last upgrade for SAB Biotherapeutics (SABS)?

A

There is no last upgrade for SAB Biotherapeutics

Q

When was the last downgrade for SAB Biotherapeutics (SABS)?

A

The last downgrade for SAB Biotherapeutics Inc happened on October 5, 2023 when Ladenburg Thalmann changed their price target from N/A to N/A for SAB Biotherapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for SAB Biotherapeutics (SABS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SAB Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SAB Biotherapeutics was filed on May 15, 2025 so you should expect the next rating to be made available sometime around May 15, 2026.

Q

Is the Analyst Rating SAB Biotherapeutics (SABS) correct?

A

While ratings are subjective and will change, the latest SAB Biotherapeutics (SABS) rating was a maintained with a price target of $20.00 to $20.00. The current price SAB Biotherapeutics (SABS) is trading at is $1.83, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch